{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:15:23Z","timestamp":1772774123471,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40121-019-00279-0","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T15:03:10Z","timestamp":1579791790000},"page":"107-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting"],"prefix":"10.1007","volume":"9","author":[{"given":"Ravina","family":"Kullar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Puzniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"Swindle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"279_CR1","unstructured":"The White House. National action plan for combating antibiotic-resistant bacteria. 2015. https:\/\/www.cdc.gov\/drugresistance\/pdf\/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf. Accessed 12 Aug 2019."},{"issue":"11","key":"279_CR2","doi-asserted-by":"publisher","first-page":"e0143276","DOI":"10.1371\/journal.pone.0143276","volume":"10","author":"KS Kaye","year":"2015","unstructured":"Kaye KS, Patel DA, Stephens JM, Khachatryan A, Patel A, Johnson K. Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact. PLoS One. 2015;10(11):e0143276.","journal-title":"PLoS One"},{"issue":"5","key":"279_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/21548331.2018.1506673","volume":"46","author":"KR Keyloun","year":"2018","unstructured":"Keyloun KR, Weber DJ, Gardstein BM, Berger A, Gillard P, Ganz ML. Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States. Hosp Pract. 2018;46(5):278\u201386.","journal-title":"Hosp Pract."},{"issue":"6","key":"279_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1469-0691.2012.03914.x","volume":"19","author":"BY Lee","year":"2013","unstructured":"Lee BY, Singh A, David MZ, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect. 2013;19(6):528\u201336.","journal-title":"Clin Microbiol Infect"},{"key":"279_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12879-015-1071-0","volume":"15","author":"LG Miller","year":"2015","unstructured":"Miller LG, Eisenberg DF, Liu H, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005\u20132010. BMC Infect Dis. 2015;15:362.","journal-title":"BMC Infect Dis"},{"key":"279_CR6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/1471-2334-14-296","volume":"14","author":"JA Suaya","year":"2014","unstructured":"Suaya JA, Mera RM, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis. 2014;14:296.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"279_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"9","key":"279_CR8","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/jac\/dks194","volume":"67","author":"A Gray","year":"2012","unstructured":"Gray A, Dryden M, Charos A. Antibiotic management and early discharge from hospital: an economic analysis. J Antimicrob Chemother. 2012;67(9):2297\u2013302.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"279_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/21548331.2015.1076325","volume":"43","author":"TP Lodise","year":"2015","unstructured":"Lodise TP, Fan W, Sulham KA. Hospital admission patterns in adult patients with skin and soft tissue infections: identification of potentially avoidable hospital admissions through a retrospective database analysis. Hosp Pract. 2015;43(3):137\u201343.","journal-title":"Hosp Pract."},{"issue":"1","key":"279_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5811\/westjem.2014.11.24133","volume":"16","author":"DA Talan","year":"2015","unstructured":"Talan DA, Salhi BA, Moran GJ, et al. Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. West J Emerg Med. 2015;16(1):89\u201397.","journal-title":"West J Emerg Med."},{"issue":"2","key":"279_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijantimicag.2016.04.023","volume":"48","author":"D Nathwani","year":"2016","unstructured":"Nathwani D, Dryden M, Garau J. Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe. Int J Antimicrob Agents. 2016;48(2):127\u201336.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"279_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1186\/s12913-018-3751-0","volume":"18","author":"SS Almarzoky Abuhussain","year":"2018","unstructured":"Almarzoky Abuhussain SS, Burak MA, Kohman KN, et al. Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. BMC Health Serv Res. 2018;18(1):932.","journal-title":"BMC Health Serv Res."},{"issue":"10","key":"279_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","volume":"23","author":"M Abbas","year":"2017","unstructured":"Abbas M, Paul M, Huttner A. New and improved? A review of novel antibiotics for gram-positive bacteria. Clin Microbiol Infect. 2017;23(10):697\u2013703.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"279_CR14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","volume":"14","author":"GJ Moran","year":"2014","unstructured":"Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6\u00a0days versus linezolid for 10\u00a0days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696\u2013705.","journal-title":"Lancet Infect Dis."},{"issue":"7","key":"279_CR15","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1128\/AAC.00431-13","volume":"57","author":"S Flanagan","year":"2013","unstructured":"Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013;57(7):3060\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"279_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jama.2013.241","volume":"309","author":"P Prokocimer","year":"2013","unstructured":"Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559\u201369.","journal-title":"JAMA"},{"issue":"2","key":"279_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1128\/AAC.03688-14","volume":"59","author":"AF Shorr","year":"2015","unstructured":"Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59(2):864\u201371.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"279_CR18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/jac\/dki092","volume":"55","author":"RA Seaton","year":"2005","unstructured":"Seaton RA, Bell E, Gourlay Y, Semple L. Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother. 2005;55(5):764\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"279_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz991","author":"M Marks","year":"2019","unstructured":"Marks M, Bell LCK, Jones I, et al. Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in OPAT. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz991(epub ahead of print).","journal-title":"Clin Infect Dis."},{"key":"279_CR20","first-page":"258","volume":"5","author":"C Mullins","year":"2013","unstructured":"Mullins C, Yang K, Onukwugha E, et al. Rehospitalizations and direct medical costs for cSSSI: linezolid versus vancomycin. Am J Pharm Benefits. 2013;5:258\u201367.","journal-title":"Am J Pharm Benefits."},{"issue":"6","key":"279_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"52","key":"279_CR22","doi-asserted-by":"publisher","first-page":"e9163","DOI":"10.1097\/MD.0000000000009163","volume":"96","author":"C De Anda","year":"2017","unstructured":"De Anda C, Anuskiewicz S, Prokocimer P, Vazquez J. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: subgroup analysis of 2 randomized phase 3 trials. Medicine (Baltimore). 2017;96(52):e9163.","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"279_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40121-018-0207-0","volume":"7","author":"S Shlyapnikov","year":"2018","unstructured":"Shlyapnikov S, Jauregui A, Khachatryan NN, et al. Real-life evidence for tedizolid phosphate in the treatment of cellulitis and wound infections: a case series. Infect Dis Ther. 2018;7(3):387\u201399.","journal-title":"Infect Dis Ther."},{"issue":"1","key":"279_CR24","first-page":"23","volume":"20","author":"P McKinnon","year":"2007","unstructured":"McKinnon P, Carter C, Girase P, Liu L, Carmeli Y. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag Care Interface. 2007;20(1):23\u201334.","journal-title":"Manag Care Interface."},{"issue":"14","key":"279_CR25","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMsa0803563","volume":"360","author":"SF Jencks","year":"2009","unstructured":"Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418\u201328.","journal-title":"N Engl J Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00279-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-019-00279-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00279-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T04:20:56Z","timestamp":1715746856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-019-00279-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["279"],"URL":"https:\/\/doi.org\/10.1007\/s40121-019-00279-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}